Physician profile
Howard Mark Wright
NPI 1952390957
$16,340.79
in general payments reported to CMS, 2019-2025
81 companies · $1,780 in 2025
The $1,780 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,026 · 2020: $2,451 · 2021: $2,812 · 2022: $2,450 · 2023: $2,128 · 2024: $1,694 · 2025: $1,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,025.74 | 2019-2025 | Otezla, Repatha, Enbrel |
| Novo Nordisk INC | $1,262.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,206.78 | 2019-2025 | |
| Lilly USA, LLC | $1,148.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $984.71 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $708.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $705.50 | 2019-2025 | |
| Amarin Pharma, INC. | $574.61 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $567.23 | 2019-2023 | Livalo, Seglentis |
| Abbvie INC. | $549.28 | 2020-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $431.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.98 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $323.94 | 2019-2025 | Vpriv |
| Janssen Pharmaceuticals, INC | $276.27 | 2019-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.67 | 2019-2025 | Xifaxan |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.